Get the Stockscreener App
296.41
0.44%
1.31
After Hours:
296.41
Charles River Laboratories International Inc stock is traded at $296.41, with a volume of 901.31K.
It is up +0.44% in the last 24 hours and up +32.15% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$295.10
Open:
$297.01
24h Volume:
901.31K
Relative Volume:
1.00
Market Cap:
$14.15B
Revenue:
$4.03B
Net Income/Loss:
$-182.84M
P/E Ratio:
-78.83
EPS:
-3.7603
Net Cash Flow:
$391.29M
1W Performance:
+1.70%
1M Performance:
+32.15%
6M Performance:
+66.07%
1Y Performance:
+82.07%
1-Day Range:
$295.93
$303.31
1-Week Range:
$289.07
$303.31
52-Week Range:
$144.26
$303.31
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
296.41 | 13.91B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
630.70 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.68 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
338.70 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
157.69 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.38 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-29-26 | Upgrade | CLSA | Hold → Outperform |
| Apr-14-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-17-25 | Upgrade | Argus | Hold → Buy |
| Nov-06-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-06-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-02-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
What Does Charles River Laboratories International (CRL) Gain From This Vaccine Collaboration? - simplywall.st
Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development? - Yahoo Finance
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running? - TradingView
Charles River Labs stock holds near fresh 52-week high after strong Q2 earnings - Ad-hoc-news.de
Are Options Traders Betting on a Big Move in Charles River Stock? - TradingView
Charles River Gains 88.6% in a Year: What's Driving the Rally? - Yahoo Finance
Madison Asset Management LLC Invests $3.81 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Labs CEO Birgit Girshick Gifts 528 Shares, Retains Significant Ownership - Kalkine Media
Charles River Laboratories Director Nancy C. Andrews Reports Form 4 Filing on Stock Option Exercise and Sale - Kalkine Media
Charles River Labs CEVP Parisotto sells $599,710 in shares By Investing.com - Investing.com Australia
Charles River Laboratories International (NYSE:CRL) Director Nancy Andrews Sells 573 Shares - MarketBeat
Charles River (NYSE: CRL) CEO makes 528-share gift of common stock - Stock Titan
Shannon Parisotto Sells 2,039 Shares of Charles River Laboratories International (NYSE:CRL) Stock - MarketBeat
Charles River Labs CEVP Parisotto sells $599,710 in shares - Investing.com
Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing - marketscreener.com
Charles River (NYSE: CRL) insider sells 2,039 shares in 10b5-1 plan - Stock Titan
Charles River (NYSE: CRL) director exercises options, sells 573 shares - Stock Titan
Charles River Labs stock hits fresh 52-week high as Medigen vaccine deal boosts sentiment - Ad-hoc-news.de
Charles River Laboratories stock hits 52-week high at $294.68 By Investing.com - Investing.com Nigeria
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing - BioSpace
Charles River Laboratories International, Inc. and Medigen Vaccine Biologics Corp. Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing - marketscreener.com
MEX:CRL EV-to-OCF: 27.30 — 36% Above Median - GuruFocus
Is Charles River Laboratories International Inc (CRL) Overvalued - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River (NYSE: CRL) officer to sell 2,039 shares after option exercise - Stock Titan
Charles (CRL) Snapshot: Moves 4.77% Up to $292.52 in the Latest Session; Levels: the $277.89 to $307.15 Range Remains in FocusMotive Wave - Vinanet
Charles (CRL) Results Versus Estimates: Profit Per Share Surpasses Its Benchmark at the Close; Trading Move - Vinanet
Charles River Laboratories International (CRL) Cut 2026 Guidance, Is The Stock Still 11% Undervalued? - simplywall.st
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Labs stock reaches new 12-month high as 2026 guidance lifts expectations - Ad-hoc-news.de
Charles River (NYSE: CRL) investor to sell 573 shares via UBS - Stock Titan
Resilient Charles River Labs stock hits new 12-month high as Q2 revenue tops $1 billion - AD HOC NEWS
Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month HighHere's Why - MarketBeat
Birgit Girshick maps out Charles River's post-divestiture future: re-accelerating growth and a lighter portfolio - The Pharma Letter
CRL Q2 2026 Earnings: EPS Surge of 9.23% Beats Estimates as Shares Nudge LowerEarnings Volatility Report - Vinanet
What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing? - Moomoo
Handelsbanken Fonder AB Increases Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Lowered 2026 EPS Outlook and Rebounding Demand Could Be A Game Changer For Charles River (CRL) - simplywall.st
If You Invested $100 In Charles River Stock 15 Years Ago, You Would Have This Much Today - Benzinga
Birgit Girshick Sells 6,500 Shares of Charles River Laboratories International (NYSE:CRL) Stock - MarketBeat
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Charles River Labs (CRL) CEO exercises 6,500 options and sells shares under 10b5-1 plan - Stock Titan
Charles River (CRL) executive Parisotto exercises options, sells 3,714 shares under 10b5-1 plan - Stock Titan
Invesco reports 2.98M-share stake in Charles River Laboratories (CRL) - Stock Titan
Charles River Laboratories stock hits 52-week high at $285.13 - Investing.com
Charles River Laboratories stock hits 52-week high at $285.13 By Investing.com - Investing.com Australia
Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript - The Globe and Mail
Charles River Laboratories International, Inc. $CRL Shares Sold by Pacer Advisors Inc. - MarketBeat
Insider Selling: Charles River Laboratories International (NYSE:CRL) Director Sells $7,901,575.00 in Stock - MarketBeat
Charles River Laboratories (CRL) EVP LaPlume reports bona fide gift of 257 shares - Stock Titan
Charles River (CRL) director James C. Foster exercises options and sells 28,733 shares - Stock Titan
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):